ArticlebioRxiv : the preprint server for biology2024
A CXCR4 partial agonist improves immunotherapy by targeting polymorphonuclear myeloid-derived suppressor cells and cancer-driven granulopoiesis.
Jin Qian et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.